The National Cancer Institute-Children's Oncology Group (NCI-COG) Pediatric Molecular Analysis for Therapy Choice (MATCH) trial provides a framework for biomarker-driven early phase trials of targeted therapies in pediatric and young adult cancer patients across the United States. Pediatric MATCH enrolled more than 1,300 patients with treatment-refractory cancers, offering access to molecular screening and investigational targeted therapies. To further advance this, matched diagnostic, refractory tumor, and normal samples from Pediatric MATCH cases were molecularly characterized, creating one of the largest comprehensive data sets available for childhood cancers. This analysis has the potential to provide novel insights into the genetics of refractory pediatric, adolescent, and young adult cancers, as well as inform potential therapeutic strategies. The following molecular characterization assays were performed: <ul><li>Tumor whole exome sequencing (WES) </li><li>Tumor whole genome sequencing (WGS) </li><li>Tumor RNA sequencing (RNA-seq) </li><li>Blood whole exome sequencing (WES) </li><li>Blood whole genome sequencing (WGS) </li></ul>

Childhood Cancer Data Initiative (CCDI): NCI-COG Pediatric MATCH    Precision Medicine Clinical Trial

Neoplasms study on dbGaP (1,239 participants)

Childhood Cancer Data Initiative (CCDI): NCI-COG Pediatric MATCH Precision Medicine Clinical Trial

Description

Applying For Access

Summary